CytoSorbents Corporation, a leading blood purification company to treat deadly inflammation diseases, has announced on Monday April 27, 2020 that the company has appointed the N. Deliargyrus. M.D, as the company’s new Chief Medical Officer.
According to the details released by the PR News Wire News Agency, the company’s new Chief Medical Officer N. Deliargyris, MD, FACC, FESC, FSCAI has over 19 years of experience in the medical industry and academic medicine before reaching to the post of Chief Medical Officer (CMO). Dr. Deliargyris also served as the European Medical Director at Munich-based Acute Cardiovascular Care and Vice President at Munich-Global Medical Lead
Chief Executive Officer of CytoSorbents, Dr. Phillip Chan, MD, said “We are thrilled to have Efthymios (“Makis”) join CytoSorbents to lead worldwide clinical activity in critical care and cardiac surgery applications during this exciting chapter at our company. His extensive expertise in cardiology, interventional cardiology, and the treatment of complications of critical illnesses such as shock, through many years of clinical practice, clinical trial research, and industry focus, make him well-suited for this task.”
Sharing his thought over the new appointment, Dr. Deliargyris said, “I am very excited about joining this talented executive team during a time of tremendous progress as evidenced by FDA Emergency Use Authorization of CytoSorb for critically-ill COVID-19 patients, and also FDA Breakthrough Designation for removal of ticagrelor during on-pump emergent and urgent cardiothoracic surgery.”
“Whether silencing the cytokine storm or eliminating the risk of life-threating bleeding, CytoSorb is a ame-changer with the potential to save thousands of lives and millions of healthcare dollars. We plan to esign and execute a world-class clinical trial program and generate the necessary data to support egulatory approvals and establish CytoSorb as a life-saving therapy in multiple indications in the ntensive care unit and cardiac surgery,” Dr. Deliargyris further added.